Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), clearing the way for the company to initiate Phase 2 clinical development of this first-in-class candidate for multiple sclerosis (MS). The upcoming trial, designed as a randomized, double-blind, placebo-controlled study, will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. The company has already begun site selection and aims to start patient enrollment and drug administration as soon as possible.
Lucid-MS is distinguished from existing MS therapies by its neuroprotective mechanism, which targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. By inhibiting demyelination, Lucid-MS aims to prevent and potentially reverse the breakdown of myelin, the underlying cause of MS progression. In preclinical models, Lucid-MS demonstrated the ability to prevent and reverse myelin breakdown. Furthermore, Phase 1 trials in healthy participants showed a favorable safety profile and good tolerability.
The approval of the IND is a critical milestone for Quantum BioPharma, which reported over $10 million in cash, digital assets, and liquid investments as of March 31, 2026. This financial position supports the advancement of Lucid-MS through Phase 2, a stage that will provide crucial data on its efficacy in patients. The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS.
“This FDA clearance allows us to move forward with our clinical program for Lucid-MS, which has the potential to offer a new therapeutic approach for MS patients,” said a company spokesperson. The significance of this development lies in the potential shift from immunomodulatory treatments to direct neuroprotection. Current MS therapies primarily modulate the immune system, but they do not directly address the myelin damage that leads to disability. If successful, Lucid-MS could fill that gap, offering a disease-modifying therapy that targets the core pathology of MS.
For more information on the full press release, visit https://ibn.fm/HyWYH. The latest news and updates regarding QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
